Display options
Cite
Cho CH, Yoon SY, Lee CK, et al. Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells. Cell J. 2015;16(4):528-37doi: 10.22074/cellj.2015.497.
Cho, C. H., Yoon, S. Y., Lee, C. K., Lim, C. S., & Cho, Y. (2015). Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells. Cell journal, 16(4), 528-37. https://doi.org/10.22074/cellj.2015.497
Cho, Chi Hyun, et al. "Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells." Cell journal vol. 16,4 (2015): 528-37. doi: https://doi.org/10.22074/cellj.2015.497
Cho CH, Yoon SY, Lee CK, Lim CS, Cho Y. Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells. Cell J. 2015;16(4):528-37. doi: 10.22074/cellj.2015.497. Epub 2015 Jan 13. PMID: 25685743; PMCID: PMC4297491.
Copy Download .nbib Format: NLM
Share it on

Cell J. 2015;16(4):528-37. doi: 10.22074/cellj.2015.497. Epub 2015 Jan 13.

Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells.

Cell journal

Chi Hyun Cho, Soo Young Yoon, Chang Kyu Lee, Chae Seung Lim, Yunjung Cho

Affiliations

  1. Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Korea.

PMID: 25685743 PMCID: PMC4297491 DOI: 10.22074/cellj.2015.497

Abstract

OBJECTIVE: The effect of interleukin (IL)-29, a new therapeutic agent similar to type I interferons (IFNs), on IFN-α secretion of human plasmacytoid dendritic cells (pDCs) has not been studied. Therefore, in this study, we aimed to clarify the effect of IL-29 on IFN-α secretion of pDCs using human peripheral blood mononuclear cells (PBMCs) in the presence of cytosine-phosphate-guanosinemotif-containing oligodeoxy nucleotides (CpG).

MATERIALS AND METHODS: In this experimental and prospective study, PBMCs were ob- tained from 11 healthy volunteers and divided into four culture conditions: I. control, II. CpG treatment, III. IL-29 treatment and IV. CpG plus IL-29 treatment. The amount of IFN-α secretion was measured from each culture supernatant by flow cytometry using the flowcytomix apparatus (eBioscience, Vienna, Austria). Fractional IFN-α production of the cultured PBMCs was measured by intracellular staining using the cytomics FC 500 system (Beckman Coulter, Brea, CA, USA) with CXP Software.

RESULTS: The mean ± standard deviation (SD) of supernatant IFN-α secretion per pDC/μL was 5.7 ± 9.3 pg/mL/count/µL for condition I, 1071.5 ± 1026.6 pg/mL/count/µL for condition II, 14.1 ± 21.1 pg/mL/count/µL for condition III, and 1913.9 ± 1525.9 pg/mL/count/µL for condition IV. There were statistically significant differences between conditions I and II as well as betweenconditions II and IV. Intracellular IFN-α production was only detectable in the pDC fraction from one culture; the production amount was similar between the cells treated with CpG and those treated with CpG plus IL-29. Natural killer (NK) cell production of IFN-α was observed in two out of three cultures and one culture showed IFN- α production in the monocyte fraction.

CONCLUSION: IL-29 alone did not show any effect on IFN-α secretion of PBMCs. However, the addition of CpG along with IL-29 enhanced IFN-α secretion of PBMCs. Given that pDCs are the major secretors of IFN-α in peripheral blood, this result has suggested the possibility that IL-29 has an enhancing effect in human pDC IFN-α secretion. Although the supernatant IFN-α secretion was not directly correlated with pDCs's intracellular IFN-α production in this study, prolonged incubation of pDC and other PB subsets with CpG or IL-29 for over 4 hours could be applied in future studies. These studies would help to elucidate the mechanism of action of IL-29 in human pDCs associated with viral infections.

Keywords: CpG; IFN-α; IL-29; Peripheral Blood; Plasmacytoid Dendritic Cells

References

  1. Clin Dev Immunol. 2011;2011:349575 - PubMed
  2. J Virol. 2005 Jan;79(1):17-27 - PubMed
  3. Immunology. 2011 Aug;133(4):409-19 - PubMed
  4. Cytokine Growth Factor Rev. 2010 Aug;21(4):237-51 - PubMed
  5. J Leukoc Biol. 2009 Dec;86(6):1359-63 - PubMed
  6. Clin Immunol. 2008 May;127(2):252-64 - PubMed
  7. Annu Rev Immunol. 2005;23:275-306 - PubMed
  8. J Infect Dis. 2012 Sep 1;206(5):790-801 - PubMed
  9. J Virol. 2008 Jun;82(11):5145-52 - PubMed
  10. Curr Opin Immunol. 2010 Apr;22(2):206-11 - PubMed
  11. Nat Genet. 2009 Oct;41(10):1048-50 - PubMed
  12. Hepatology. 2005 Mar;41(3):643-51 - PubMed
  13. Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E519-20; author reply E521-2 - PubMed
  14. Front Immunol. 2013 Jan 04;3:403 - PubMed
  15. J Innate Immun. 2011;3(3):258-63 - PubMed
  16. J Intern Med. 2009 Jan;265(1):43-57 - PubMed
  17. J Immunol. 2008 Feb 15;180(4):2474-85 - PubMed
  18. J Virol. 2008 Apr;82(8):3997-4006 - PubMed
  19. J Immunol. 2006 Oct 1;177(7):4841-52 - PubMed
  20. Int Immunol. 2012 Jun;24(6):347-56 - PubMed
  21. J Immunol. 2005 Jul 15;175(2):806-12 - PubMed
  22. J Biol Chem. 2008 Oct 31;283(44):30079-89 - PubMed
  23. Crit Rev Immunol. 2008;28(1):61-94 - PubMed
  24. Blood. 2009 Apr 9;113(15):3418-27 - PubMed

Publication Types